Haijun Yu
Auto-generated profile, based on publicly available information

Haijun Yu

State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2016 in ACS Nano
Verified
Journal Article
Closed access
HCHaiqiang Cao
Haiqiang Cao
ZDZhaoling Dan
Zhaoling Dan
XHXinyu He
Xinyu He
ZZZhiwen Zhang
Zhiwen Zhang
HYHaijun Yu
Haijun Yu
YLYaping Li
Yaping Li

15 September 2016 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
HSHuiping Sun
Huiping Sun
JSJinghan Su
Jinghan Su
QMQingshuo Meng
Qingshuo Meng
QYQi Yin
Qi Yin
LCLingli Chen
Lingli Chen
Yaping LiYaping Li
Yaping Li

14 February 2019 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
FZFangyuan Zhou
Fangyuan Zhou
BFBing Feng
Bing Feng
HYHaijun Yu
Haijun Yu
DWDangge Wang
Dangge Wang
TWTingting Wang
Tingting Wang
Yaping LiYaping Li
Yaping Li

31 July 2018 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
BFBing Feng
Bing Feng
FZFangyuan Zhou
Fangyuan Zhou
BHBo Hou
Bo Hou
DWDangge Wang
Dangge Wang
TWTingting Wang
Tingting Wang
Yaping LiYaping Li
Yaping Li

17 August 2016 in Nano Letters
Verified
Journal Article
Closed access
DWDangge Wang
Dangge Wang
TWTingting Wang
Tingting Wang
JLJianping Liu
Jianping Liu
HYHaijun Yu
Haijun Yu
SJShi Jiao
Shi Jiao
Yaping LiYaping Li
Yaping Li

18 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
TWTingting Wang
Tingting Wang
DWDangge Wang
Dangge Wang
HYHaijun Yu
Haijun Yu
BFBing Feng
Bing Feng
FZFangyuan Zhou
Fangyuan Zhou
Yaping LiYaping Li
Yaping Li
Vaccines to induce effective and sustained antitumor immunity have great potential for postoperative cancer therapy. However, a robust cancer vaccine simultaneously eliciting tumor-specific immunity and abolishing immune resistance continues to be a challenge. Here we present a personalized cancer vaccine (PVAX) for postsurgical immunotherapy. PVAX is developed by encapsulating JQ1 (a BRD4 inhibitor) and indocyanine green (ICG) co-loaded tumor cells with a hydrogel matrix. Activation of PVAX by 808 nm NIR laser irradiation significantly inhibits the tumor relapse by promoting the maturation of dendritic cells and eliciting tumor infiltration of cytotoxic T lymphocytes. A mechanical study reveals that NIR light-triggered antigen release and JQ1-mediated PD-L1 checkpoint blockade cumulatively contribute to the satisfied therapeutic effect. Furthermore, PVAX prepared from the autologous tumor cells induces patient-specific memory immune response to prevent tumor recurrence and metastasis. The PVAX model might provide novel insights for postoperative immunotherapy.